Celebrating the 12th Annual

Canadian Hematology Conference 2022

About CHC 2022

Join us for the 12th annual Canadian Hematology Conference (Virtual)
on September 30th – October 1st

CHC 2022 was held on a virtual streaming platform, running September 30th – October 1st.

CHC is the largest multi-disciplinary hematological conference across Canada. It brings together a pan-Canadian and International Faculty to showcase cutting-edge research and developments in the field of hematology.

Dr. John Kuruvilla (Princess Margaret Cancer Centre) and Dr. Peter Anglin (Stronach Regional Cancer Centre) will co-chair this event. CHC 2022 is open to Canadian hematology professionals, including residents, nurses, pharmacists, and specialists who have an interest in hematology.

Register to gain access to:

  • Leading clinical presentations
  • Panelist discussions / Q&A
  • First access to clinical slide decks
  • Year-round access to recorded CHC 2022 presentations

Access the CHC 2022 Report
for Videos on-Demand!

Featuring: Speaker Bios, Presentations, Q&As, Powerpoints
Click Here

Event Chairs

Dr. John Kuruvilla
Princess Margaret Cancer Centre

Dr. Peter Anglin
Stronach Regional Cancer Centre


Presentations and timing follow:

Day 01

September 30th 2022   |   9:00AM–6:00PM [EST]

9:00 — Opening Remarks


9:05 Aggressive B-cell Lymphoma

Frontline Therapy [ + Q&A ]
Dr. Laurie Sehn, BCCA, Vancouver

Second Line (And Beyond) [ + Q&A ]
Dr. Michael Crump, PMCC, Toronto

10:21 — Break


10:36 Indolent (Follicular and Mantle Cell) Lymphoma

Managing patients with Relapsed/Refractory Follicular Lymphoma [ + Q&A ]
Dr. Gilles Salles, Memorial Sloan Kettering, NY

Recent Advances in the Management of Mantle Cell Lymphoma [ + Q&A ]
Dr. Diego Villa, BCCA, Vancouver

Advances in BiTE Therapy for Lymphoma [ + Q&A ]
Rob Laister PhD, PMCC, Toronto

12:32 — Lunch Break


13:00 Hodgkin Lymphoma

Approaches in Frontline Advanced Hodgkin Lymphoma
[ + Q&A ]

Dr. Alison Moskowitz, Memorial Sloan Kettering, New York

Primary Treatment of Localized Hodgkin Lymphoma
Dr. John Kuruvilla, PMCC, Toronto

Hodgkin Lymphoma: Future Directions in Treatment
Dr. Stephen Ansell, Mayo Clinic, Rochester, MN

— Break


14:45 Plasma Cell Dyscrasias

Newly Diagnosed Multiple Myeloma [ + Q&A ]
Dr. Keith Stewart, PMCC, Toronto

Multiple Myeloma – Relapsed Disease [ + Q&A ]
Dr. Rafael Fonseca, Mayo Clinic, Arizona

New Agents in Multiple Myeloma
Dr. Paola Neri, Arnie Charbonneau Cancer Institute, Calgary

— Break

Myeloid Leukemia

AML: The Evolving Landscape of Frontline Therapy
a. intensive induction
b. non-intensive induction

Dr. Guillaume Richard-Carpentier, PMCC, Toronto

17:58 — Closing Remarks

Day 02

October 1st 2022   |   9:00AM–1:00PM [EST]

9:00 — Opening Remarks


9:05 Chronic Lymphocytic Leukemia

Frontline CLL Treatment [ + Q&A ]
Dr. Stephan Stilgenbauer, Ulm University, Germany

Management of CLL in the Relapsed Setting: a Canadian Perspective [ + Q&A ]
Dr. Versha Banerji, CancerCare Manitoba, Winnipeg

10:15 CLL Supplementary Symposium

BTK Inhibitors in CLL: Current standards of care and emerging data
Dr. Jennifer Brown, Dana-Farber Cancer Institute, Boston

10:54 — Break

Challenges in Hematology in Canada

Cancer Care for Indigenous People
Tobi Mitchell, Director of Health – Chiefs of Ontario

11:10 Recap of last two days

Key pearls and highlights

— Closing Remarks